Header Logo

Connection

Lynn Morris to Molecular Sequence Data

This is a "connection" page, showing publications Lynn Morris has written about Molecular Sequence Data.
Connection Strength

1,756
  1. Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. J Virol. 2013 May; 87(9):4882-94.
    View in: PubMed
    Score: 0,102
  2. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med. 2012 Nov; 18(11):1688-92.
    View in: PubMed
    Score: 0,100
  3. Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol. 2009 Nov; 83(21):11265-74.
    View in: PubMed
    Score: 0,080
  4. 4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response. J Virol. 2008 Mar; 82(5):2367-75.
    View in: PubMed
    Score: 0,071
  5. N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization. J Virol. 2007 Oct; 81(19):10769-76.
    View in: PubMed
    Score: 0,069
  6. Polymorphisms in Nef associated with different clinical outcomes in HIV type 1 subtype C-infected children. AIDS Res Hum Retroviruses. 2007 Feb; 23(2):204-15.
    View in: PubMed
    Score: 0,067
  7. Longitudinal analysis of HIV type 1 subtype C envelope sequences from South Africa. AIDS Res Hum Retroviruses. 2007 Feb; 23(2):316-21.
    View in: PubMed
    Score: 0,067
  8. High specificity of V3 serotyping among human immunodeficiency virus type-1 subtype C infected patients with varying disease status and viral phenotype. J Med Virol. 2006 Oct; 78(10):1262-8.
    View in: PubMed
    Score: 0,066
  9. Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. Virology. 2006 Dec 5-20; 356(1-2):95-105.
    View in: PubMed
    Score: 0,065
  10. Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Med. 2006 Jul; 3(7):e255.
    View in: PubMed
    Score: 0,065
  11. Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression. AIDS Res Hum Retroviruses. 2006 May; 22(5):458-65.
    View in: PubMed
    Score: 0,064
  12. In vitro generation of HIV type 1 subtype C isolates resistant to enfuvirtide. AIDS Res Hum Retroviruses. 2005 Sep; 21(9):776-83.
    View in: PubMed
    Score: 0,061
  13. Use of alternate coreceptors on primary cells by two HIV-1 isolates. Virology. 2005 Aug 15; 339(1):136-44.
    View in: PubMed
    Score: 0,061
  14. Characterization of human immunodeficiency virus type 1 from a previously unexplored region of South Africa with a high HIV prevalence. AIDS Res Hum Retroviruses. 2005 Jan; 21(1):103-9.
    View in: PubMed
    Score: 0,058
  15. Sensitivity of HIV type 1 subtype C isolates to the entry inhibitor T-20. AIDS Res Hum Retroviruses. 2004 May; 20(5):477-82.
    View in: PubMed
    Score: 0,056
  16. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol. 2003 Apr; 77(7):4449-56.
    View in: PubMed
    Score: 0,051
  17. HIV-1 subtype C reverse transcriptase sequences from drug-naive pregnant women in South Africa. AIDS Res Hum Retroviruses. 2002 May 20; 18(8):605-10.
    View in: PubMed
    Score: 0,048
  18. Phylogenetic analysis of human herpesvirus-8 in South Africa and identification of a novel subgroup. J Gen Virol. 2000 Aug; 81(Pt 8):2029-2038.
    View in: PubMed
    Score: 0,043
  19. Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. Cell Rep. 2016 Jan 05; 14(1):43-54.
    View in: PubMed
    Score: 0,031
  20. New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. J Virol. 2016 01 01; 90(1):76-91.
    View in: PubMed
    Score: 0,031
  21. Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. Cell Host Microbe. 2015 Sep 09; 18(3):354-62.
    View in: PubMed
    Score: 0,030
  22. Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients. AIDS Res Hum Retroviruses. 2015 Aug; 31(8):776-82.
    View in: PubMed
    Score: 0,030
  23. Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. Immunity. 2014 Dec 18; 41(6):909-18.
    View in: PubMed
    Score: 0,029
  24. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature. 2014 Oct 23; 514(7523):455-61.
    View in: PubMed
    Score: 0,029
  25. Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. Cell Host Microbe. 2014 Sep 10; 16(3):304-13.
    View in: PubMed
    Score: 0,028
  26. A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1. J Biol Chem. 2014 Oct 24; 289(43):29912-26.
    View in: PubMed
    Score: 0,028
  27. HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria. Cell Host Microbe. 2014 Aug 13; 16(2):215-226.
    View in: PubMed
    Score: 0,028
  28. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014 May 01; 509(7498):55-62.
    View in: PubMed
    Score: 0,027
  29. Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. J Virol. 2013 Jul; 87(13):7218-33.
    View in: PubMed
    Score: 0,026
  30. Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C. J Acquir Immune Defic Syndr. 2011 Jan 01; 56(1):9-15.
    View in: PubMed
    Score: 0,022
  31. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 2009 Sep; 5(9):e1000598.
    View in: PubMed
    Score: 0,020
  32. Functional and genetic analysis of coreceptor usage by dualtropic HIV-1 subtype C isolates. Virology. 2009 Oct 10; 393(1):56-67.
    View in: PubMed
    Score: 0,020
  33. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology. 2009 May 10; 387(2):414-26.
    View in: PubMed
    Score: 0,019
  34. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis. 2009 Feb 15; 48(4):462-72.
    View in: PubMed
    Score: 0,019
  35. Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. Virology. 2009 Mar 15; 385(2):505-20.
    View in: PubMed
    Score: 0,019
  36. The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J Virol. 2008 Feb; 82(4):1860-9.
    View in: PubMed
    Score: 0,018
  37. A model of directional selection applied to the evolution of drug resistance in HIV-1. Mol Biol Evol. 2007 Apr; 24(4):1025-31.
    View in: PubMed
    Score: 0,017
  38. Resistance mutational analysis of HIV type 1 subtype C among rural South African drug-naive patients prior to large-scale availability of antiretrovirals. AIDS Res Hum Retroviruses. 2006 Dec; 22(12):1306-12.
    View in: PubMed
    Score: 0,017
  39. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol. 2006 Dec; 80(23):11776-90.
    View in: PubMed
    Score: 0,016
  40. HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes. AIDS. 2006 Mar 21; 20(5):643-51.
    View in: PubMed
    Score: 0,016
  41. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2005 Apr; 2(4):e112.
    View in: PubMed
    Score: 0,015
  42. Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses. 2003 Feb; 19(2):133-44.
    View in: PubMed
    Score: 0,013
  43. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol. 2002 Mar; 76(5):2233-44.
    View in: PubMed
    Score: 0,012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.